LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Zynex to Participate at the Needham Annual Growth Conference

January 08, 2024 | Last Trade: US$2.16 0.00 0.00

ENGLEWOOD, Colo., Jan. 8, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will participate virtually in the upcoming Needham Annual Growth Conference, which is being held January 16th-19th, 2024.

Dan Moorhead, CFO, will be available for one-on-one meetings on January 16th and 19th.

To receive additional information, register to attend, or schedule a one-on-one meeting, email the Needham team at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page